APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. |
|
|
| Recruiting | 3 | 192 | RoW | Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment | Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 12/24 | 12/26 | | |
NCT06136988: A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. |
|
|
| Not yet recruiting | 1/2 | 129 | RoW | Docetaxel for Injection (Albumin-bound), HB1801, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, Cisplatin for injection, Paclitaxel, Simultaneous Radiotherapy | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced Unresectable Esophageal Squamous Carcinoma | 04/27 | 04/28 | | |
